Diabetes: Multifaceted Approaches to Address Adherence, Cost, and Improved Outcomes
Diabetes is the leading cost driver for clients, accounting for more than 10% of total drug expenditures, and these numbers continue to rise as the diabetes epidemic continues. Diabetes is the most expensive therapy class in traditional drug spending, and higher than specialty therapeutic classes such as oncology, multiple sclerosis, and HIV. Adherence rates for diabetes medications continue to be less than optimal, and overall hemoglobin A1c does not appear to be trending down despite increases in drugs and costs.
This webinar discusses a multifaceted approach on how to manage spend via different utilization management strategies, identify and address adherence issues from a global perspective, improve clinical pathway selections, and increase patient engagement to drive clinical outcomes.
Patty Taddei-Allen, PharmD, BCACP, BCGP, Director, Outcomes Research, WellDyneRx
Nick Page, PharmD, Vice President, Specialty and Clinical Operations, WellDyneRx
View the webcast